3-deazaneplanocin has been researched along with tamoxifen in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, HW; Han, F; Liu, P; Wang, J; Wang, Q; Xiang, S; Xu, J; Zheng, J; Zou, JX | 1 |
1 other study(ies) available for 3-deazaneplanocin and tamoxifen
| Article | Year |
|---|---|
S-adenosylhomocysteine (AdoHcy)-dependent methyltransferase inhibitor DZNep overcomes breast cancer tamoxifen resistance via induction of NSD2 degradation and suppression of NSD2-driven redox homeostasis.
Topics: Adenosine; Antigens, Ly; Apoptosis; Cell Line, Tumor; Cell Survival; Gene Expression Regulation; Histone-Lysine N-Methyltransferase; Homeostasis; Humans; Methyltransferases; Oxidation-Reduction; Proteolysis; Reactive Oxygen Species; Repressor Proteins; S-Adenosylhomocysteine; Tamoxifen; Urokinase-Type Plasminogen Activator | 2020 |